TY - JOUR
T1 - Age-adjusted Charlson comorbidity index is a significant prognostic factor for long-term survival of patients with high-risk prostate cancer after radical prostatectomy
T2 - a Bayesian model averaging approach
AU - Lee, Joo Yong
AU - Kang, Ho Won
AU - Rha, Koon Ho
AU - Cho, Nam Hoon
AU - Choi, Young Deuk
AU - Hong, Sung Joon
AU - Cho, Kang Su
N1 - Funding Information:
This study was supported by a Grant from the Korean Foundation for Cancer Research (CB-2011-04-02), Republic of Korea.
Publisher Copyright:
© 2015, Springer-Verlag Berlin Heidelberg.
PY - 2016/4/1
Y1 - 2016/4/1
N2 - Purpose: We investigated the long-term prognostic impact of age-adjusted Charlson comorbidity index (ACCI) on overall mortality (OM), cancer-specific mortality (CSM), and other-cause mortality (OCM) according to risk stratification in patients with prostate cancer who underwent radical prostatectomy. Methods: Data from 542 patients who underwent radical prostatectomy between 1992 and 2006 were analyzed. The impact of preoperative variables including age, prostate-specific antigen, biopsy Gleason sum, clinical stage, and ACCI on OM, CSM, and OCM were analyzed according to risk groups, with a median follow-up of 101 months. Results: Subjects were stratified into either the high-risk group (n = 241) or the non-high-risk group (n = 301). Cox proportional hazards model demonstrated that the ACCI was the only significant predictor for OM in all patients (hazard ratio, HR 1.41; 95 % confidence interval, CI 1.19–1.66), non-high-risk group (HR 1.45; 95 % CI 1.09–1.91), and high-risk group (HR 1.37; 95 % CI 1.11–1.69). In competing risk analysis, CSM was not associated with the ACCI in either risk group. However, the ACCI had a significant impact on OCM in both the non-high-risk (HR 1.55; 95 % CI 1.16–2.1) and high-risk groups (HR 1.60; 95 % CI 1.23–2.08). A Bayesian model averaging approach verified that the ACCI was the most powerful predictor for OM and OCM in the both high-risk and non-high-risk groups. Conclusions: A thorough assessment of comorbidities is mandatory in establishing prognoses, even when considering invasive treatment modalities in high-risk prostate cancer patients.
AB - Purpose: We investigated the long-term prognostic impact of age-adjusted Charlson comorbidity index (ACCI) on overall mortality (OM), cancer-specific mortality (CSM), and other-cause mortality (OCM) according to risk stratification in patients with prostate cancer who underwent radical prostatectomy. Methods: Data from 542 patients who underwent radical prostatectomy between 1992 and 2006 were analyzed. The impact of preoperative variables including age, prostate-specific antigen, biopsy Gleason sum, clinical stage, and ACCI on OM, CSM, and OCM were analyzed according to risk groups, with a median follow-up of 101 months. Results: Subjects were stratified into either the high-risk group (n = 241) or the non-high-risk group (n = 301). Cox proportional hazards model demonstrated that the ACCI was the only significant predictor for OM in all patients (hazard ratio, HR 1.41; 95 % confidence interval, CI 1.19–1.66), non-high-risk group (HR 1.45; 95 % CI 1.09–1.91), and high-risk group (HR 1.37; 95 % CI 1.11–1.69). In competing risk analysis, CSM was not associated with the ACCI in either risk group. However, the ACCI had a significant impact on OCM in both the non-high-risk (HR 1.55; 95 % CI 1.16–2.1) and high-risk groups (HR 1.60; 95 % CI 1.23–2.08). A Bayesian model averaging approach verified that the ACCI was the most powerful predictor for OM and OCM in the both high-risk and non-high-risk groups. Conclusions: A thorough assessment of comorbidities is mandatory in establishing prognoses, even when considering invasive treatment modalities in high-risk prostate cancer patients.
UR - http://www.scopus.com/inward/record.url?scp=84961175600&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=84961175600&partnerID=8YFLogxK
U2 - 10.1007/s00432-015-2093-0
DO - 10.1007/s00432-015-2093-0
M3 - Article
C2 - 26660495
AN - SCOPUS:84961175600
VL - 142
SP - 849
EP - 858
JO - Journal of Cancer Research and Clinical Oncology
JF - Journal of Cancer Research and Clinical Oncology
SN - 0171-5216
IS - 4
ER -